Philip Morris International Inc. has announced it will double the planned capital outlay for its Colorado manufacturing complex producing Zyn nicotine pouches, raising the total to $1.2 billion through 2028 from an initial $600 million pledged in 2024.
The facility, located in Aurora roughly 10 miles east of Denver, has recently started manufacturing operations. The decision to expand funding comes as the nicotine pouch segment encounters mounting competitive pressure from rival offerings, including British American Tobacco Plc’s Velo Plus.
Zyn remains a core element in Philip Morris’ strategy to shift away from traditional cigarettes as consumers move toward smoke-free alternatives. Although Zyn still leads the nicotine pouch category, the arrival of newer competitive products has put pressure on its market position.
The infusion of capital will increase domestic production capability at the Aurora campus as Philip Morris steps up manufacture of Zyn Ultra, which rolled out in the United States in June. Zyn Ultra is positioned as a product iteration offering a softer texture and higher nicotine strength - changes the company attributes to evolving consumer preferences.
This release marks the first substantive update to the Zyn product line in a decade; Philip Morris had held off on launching new variants while awaiting clearance from the U.S. Food and Drug Administration. The Aurora site will not only serve U.S. demand but will also supply markets across Asia, Latin America and the Caribbean.
By enlarging the plant’s funding and capacity, Philip Morris aims to secure broader manufacturing bandwidth for the Zyn franchise as competition and consumer tastes in the nicotine-pouch space change. The company’s expanded commitment to the Aurora campus underscores its emphasis on scaling production for the new Zyn formulation while distributing product to both domestic and international markets.
What the company said about the plant:
- The Aurora facility has begun production and will scale to accommodate increased demand.
- The additional investment raises total planned spending on the campus to $1.2 billion through 2028.
- The site will produce Zyn Ultra for U.S. consumption and ship to markets in Asia, Latin America and the Caribbean.